 |
Journal articles
Complex interplay between {beta}-catenin signalling and Notch effectors in intestinal tumorigenesis.
Abstract : Aims The activation of β-catenin signalling is a key step in intestinal tumorigenesis. Interplay between the β-catenin and Notch pathways during tumorigenesis has been reported, but the mechanisms involved and the role of Notch remain unclear. Methods Notch status was analysed by studying expression of the Notch effector Hes1 and Notch ligands/receptors in human colorectal cancer (CRC) and mouse models of Apc mutation. A genetic approach was used, deleting the Apc and RBP-J or Atoh1 genes in murine intestine. CRC cell lines were used to analyse the control of Hes1 and Atoh1 by β-catenin signalling. Results Notch signalling was found to be activated downstream from β-catenin. It was rapidly induced and maintained throughout tumorigenesis. Hes1 induction was mediated by β-catenin and resulted from both the induction of the Notch ligand/receptor and Notch-independent control of the Hes1 promoter by β-catenin. Surprisingly, the strong phenotype of unrestricted proliferation and impaired differentiation induced by acute Apc deletion in the intestine was not rescued by conditional Notch inactivation. Hyperactivation of β-catenin signalling overrode the forced differention induced by Notch inhibition, through the downregulation of Atoh1, a key secretory determinant factor downstream of Notch. This process involves glycogen synthase kinase 3 β (GSK3β) and proteasome-mediated degradation. The restoration of Atoh1 expression in CRC cell lines displaying β-catenin activation was sufficient to increase goblet cell differentiation, whereas genetic ablation of Atoh1 greatly increased tumour formation in Apc mutant mice. Conclusion Notch signalling is a downstream target of β-catenin hyperactivation in intestinal tumorigenesis. However, its inhibition had no tumour suppressor effect in the context of acute β-catenin activation probably due to the downregulation of Atoh1. This finding calls into question the use of γ-secretase inhibitors for the treatment of CRC and suggests that the restoration of Atoh1 expression in CRC should be considered as a therapeutic approach.
Cited literature [33 references]
https://www.hal.inserm.fr/inserm-00553865
Contributor : Béatrice Romagnolo <>
Submitted on : Monday, January 10, 2011 - 9:52:14 AM
Last modification on : Thursday, January 14, 2021 - 11:10:02 AM
Long-term archiving on: : Tuesday, September 18, 2012 - 1:10:08 PM
Contributor : Béatrice Romagnolo <>
Submitted on : Monday, January 10, 2011 - 9:52:14 AM
Last modification on : Thursday, January 14, 2021 - 11:10:02 AM
Long-term archiving on: : Tuesday, September 18, 2012 - 1:10:08 PM
File
PeignonGut.pdf
Publisher files allowed on an open archive